Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

Next Previous
Trial Profile

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Paclitaxel (Primary) ; Pumitamig (Primary) ; Topotecan (Primary) ; Topotecan (Primary) ; Alkylating agents; DNA topoisomerase I inhibitors; DNA topoisomerase I inhibitors; Taxanes
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioNTech

Most Recent Events

  • 08 Sep 2025 According to a BioNTech media release, interim data from this study confirm dose selection for the ongoing global pivotal Phase 3 ROSETTA LUNG-01 trial.
  • 08 Sep 2025 According to a BioNTech media release, the company presented interim data of 43 patients from a global randomized Phase 2 trial (NCT06449209) evaluating pumitamig (August 7, 2025 data cut-off), on 8 Sep 2025 as a late-breaker oral presentation at the IASLC 2025 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Barcelona.
  • 08 Sep 2025 Interim results presented in the BioNTech Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top